Coherus BioSciences is set to become the first company to offer biosimilars to Amgen’s complete range of Neulasta (pegfilgrastim) products, after obtaining approval from the US Food and Drug Administration for the company’s version of the Neulasta Onpro on-body injector device using Coherus’ Udenyca (pegfilgrastim-cbqv) biosimilar.
Coherus Eyeing US Pegfilgrastim Bulk With On-Body Injector Approval
Amgen’s Onpro Version Commands the >40% Of The US Market
Coherus has roared into the new year with a US FDA approval that has long been on its radar: the company’s debut rival to the Neulasta Onpro on-body injector device using Coherus’ Udenyca (pegfilgrastim-cbqv) biosimilar.
